Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2025 value amounting to $0.07.

  • Theravance Biopharma's EPS (Weighted Average and Diluted) rose 12692.31% to $0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.57, marking a year-over-year increase of 15643.56%. This contributed to the annual value of -$1.31 for FY2024, which is 3100.29% down from last year.
  • As of Q3 2025, Theravance Biopharma's EPS (Weighted Average and Diluted) stood at $0.07, which was up 12692.31% from $1.08 recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EPS (Weighted Average and Diluted) ranged from a high of $12.14 in Q3 2022 and a low of -$1.35 during Q1 2021
  • Its 5-year average for EPS (Weighted Average and Diluted) is $0.3, with a median of -$0.28 in 2023.
  • Per our database at Business Quant, Theravance Biopharma's EPS (Weighted Average and Diluted) skyrocketed by 169736.84% in 2022 and then plummeted by 17817.95% in 2024.
  • Quarter analysis of 5 years shows Theravance Biopharma's EPS (Weighted Average and Diluted) stood at -$0.78 in 2021, then surged by 73.08% to -$0.21 in 2022, then grew by 19.05% to -$0.17 in 2023, then crashed by 178.18% to -$0.47 in 2024, then surged by 114.8% to $0.07 in 2025.
  • Its last three reported values are $0.07 in Q3 2025, $1.08 for Q2 2025, and -$0.27 during Q1 2025.